MAC Lung Disease Market Poised for Growth Across the 7MM During the Forecast Period (2025-2034) Amid Rising Prevalence and New Therapeutic Solutions | DelveInsight

The MAC lung disease market is predicted to grow in the coming years. This growth is mainly driven by the launch of innovative therapies such as MNKD-101, Bedaquiline fumarate (TMC207), and SPR720, among others. Furthermore, the increasing prevalence of MAC lung disease, influenced by host factors like advanced age, COPD, thoracic abnormalities, and environmental exposure to MAC in soil, water, and aerosol-generating activities, is expected to expand the MAC lung disease market potential.

LAS VEGAS, May 20, 2025 /PRNewswire/ -- Mycobacterium avium Complex (MAC) refers to a group of bacteria, primarily Mycobacterium avium and Mycobacterium intracellulare, that are responsible for MAC lung disease. Accurate identification typically requires genetic testing. MAC is the leading cause of nontuberculous mycobacterial (NTM) lung infections in the United States and can affect people of all ages, although it is more common in older adults, postmenopausal women, smokers, and individuals with weakened immune systems or pre-existing lung conditions such as bronchiectasis, COPD, cystic fibrosis, emphysema, or a prior history of tuberculosis. 

DelveInsight estimates that in 2023, there were around 119K diagnosed prevalent cases of MAC lung disease across the 7MM, with the United States accounting for approximately 64% of these cases. In 2023, there were an estimated 151K diagnosed prevalent cases of NTM lung disease across the 7MM, with the number expected to rise by 2034.

Treatment for MAC lung disease typically involves a combination of multiple antibiotics, most often including a macrolide (such as azithromycin or clarithromycin), a rifamycin (such as rifampin or rifabutin), and ethambutol. This regimen works by inhibiting protein synthesis, disrupting the bacterial cell wall, and preventing replication of the mycobacteria. Therapy generally continues for 12 to 18 months, depending on the severity of the disease and the pathogen's drug susceptibility.

Supportive therapies play an important role, especially for patients with preexisting lung conditions. Chest physiotherapy, mucolytic agents, and bronchodilators help clear mucus and alleviate airway obstruction. Additionally, devices like positive expiratory pressure (PEP) masks and high-frequency chest wall oscillation (HFCWO) devices can assist in reducing bacterial burden.

Schreibe Deinen Kommentar